 | • レポートコード：MRC2305B137 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、252ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医療 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社は、世界のファブリー病治療市場規模が2021年に2,134.00百万ドル、2022年に2,308.83百万ドルとなり、今後年平均8.36％拡大して2027年には3,456.52百万ドルまで成長すると予測しています。当市場調査レポートは、ファブリー病治療の世界市場を多面的に分析し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、治療タイプ別（シャペロン療法、酵素補充療法、臓器別療法、基質減少療法）分析、薬剤別（アガルシダーゼベータ、ミガーラスタット、パイプライン薬）分析、投与経路別（静脈内投与、経口投与）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報などの構成でまとめました。また、当書には、Amicus Therapeutics Inc.、Avrobio Inc.、Greenovation Biotech GmbH、Idorsia Pharmaceuticals Ltd.、ISU Abxis Co Ltd.、JCR Pharmaceuticals Co Ltd.、Moderna Therapeutics Inc.、Protalix Biotherapeutics Inc.、Sanofi S.A.、Shire Plc.などの企業情報が含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界のファブリー病治療市場規模：治療タイプ別 - シャペロン療法の市場規模 - 酵素補充療法の市場規模 - 臓器別療法の市場規模 - 基質減少療法の市場規模 ・世界のファブリー病治療市場規模：薬剤別 - アガルシダーゼベータの市場規模 - ミガーラスタットの市場規模 - パイプライン薬の市場規模 ・世界のファブリー病治療市場規模：投与経路別 - 静脈内投与の市場規模 - 経口投与の市場規模 ・世界のファブリー病治療市場規模：地域別 - 南北アメリカのファブリー病治療市場規模 アメリカのファブリー病治療市場規模 カナダのファブリー病治療市場規模 ブラジルのファブリー病治療市場規模 ... - アジア太平洋のファブリー病治療市場規模 日本のファブリー病治療市場規模 中国のファブリー病治療市場規模 インドのファブリー病治療市場規模 韓国のファブリー病治療市場規模 台湾のファブリー病治療市場規模 ... - ヨーロッパ/中東/アフリカのファブリー病治療市場規模 イギリスのファブリー病治療市場規模 ドイツのファブリー病治療市場規模 フランスのファブリー病治療市場規模 ロシアのファブリー病治療市場規模 ... - その他地域のファブリー病治療市場規模 ・競争状況 ・企業情報 |
The Global Fabry Disease Treatment Market size was estimated at USD 2,134.00 million in 2021 and expected to reach USD 2,308.83 million in 2022, and is projected to grow at a CAGR 8.36% to reach USD 3,456.52 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Fabry Disease Treatment to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Treatment Type, the market was studied across Chaperone Treatment, Enzyme Replacement Therapy, Organ-specific Treatment, and Substrate Reduction Therapy.
Based on Drugs, the market was studied across Agalsidase Beta, Migalastat, and Pipeline Drugs.
Based on Route of Administration, the market was studied across Intravenous and Oral.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Fabry Disease Treatment market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Fabry Disease Treatment Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Fabry Disease Treatment Market, including Amicus Therapeutics Inc., Avrobio Inc., Greenovation Biotech GmbH, Idorsia Pharmaceuticals Ltd., ISU Abxis Co Ltd., JCR Pharmaceuticals Co Ltd., Moderna Therapeutics Inc., Protalix Biotherapeutics Inc., Sanofi S.A., and Shire Plc..
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Fabry Disease Treatment Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Fabry Disease Treatment Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Fabry Disease Treatment Market?
4. What is the competitive strategic window for opportunities in the Global Fabry Disease Treatment Market?
5. What are the technology trends and regulatory frameworks in the Global Fabry Disease Treatment Market?
6. What is the market share of the leading vendors in the Global Fabry Disease Treatment Market?
7. What modes and strategic moves are considered suitable for entering the Global Fabry Disease Treatment Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing demand for messenger RNA as a treatment modality for Fabry disease
5.1.1.2. Adoption of novel therapies
5.1.1.3. Growing incidences of genetic disorders and increasing awareness
5.1.2. Restraints
5.1.2.1. Lack of awareness about advancements with respect to treatments for Fabry disease
5.1.2.2. High cost associated with the enzyme replacement therapy
5.1.3. Opportunities
5.1.3.1. Ongoing research and development for the treatment of Fabry disease
5.1.3.2. Increasing healthcare expenditure and improving infrastructure in emerging economies
5.1.3.3. Increasing number of clinical trials
5.1.4. Challenges
5.1.4.1. Limitations in adopting new technologies in certain countries
5.2. Cumulative Impact of COVID-19
6. Fabry Disease Treatment Market, by Treatment Type
6.1. Introduction
6.2. Chaperone Treatment
6.3. Enzyme Replacement Therapy
6.4. Organ-specific Treatment
6.5. Substrate Reduction Therapy
7. Fabry Disease Treatment Market, by Drugs
7.1. Introduction
7.2. Agalsidase Beta
7.3. Migalastat
7.4. Pipeline Drugs
8. Fabry Disease Treatment Market, by Route of Administration
8.1. Introduction
8.2. Intravenous
8.3. Oral
9. Americas Fabry Disease Treatment Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Fabry Disease Treatment Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Fabry Disease Treatment Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis, By Key Player
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion
13. Company Usability Profiles
13.1. Amicus Therapeutics Inc.
13.1.1. Business Overview
13.1.2. Key Executives
13.1.3. Product & Services
13.2. Avrobio Inc.
13.2.1. Business Overview
13.2.2. Key Executives
13.2.3. Product & Services
13.3. Greenovation Biotech GmbH
13.3.1. Business Overview
13.3.2. Key Executives
13.3.3. Product & Services
13.4. Idorsia Pharmaceuticals Ltd.
13.4.1. Business Overview
13.4.2. Key Executives
13.4.3. Product & Services
13.5. ISU Abxis Co Ltd.
13.5.1. Business Overview
13.5.2. Key Executives
13.5.3. Product & Services
13.6. JCR Pharmaceuticals Co Ltd.
13.6.1. Business Overview
13.6.2. Key Executives
13.6.3. Product & Services
13.7. Moderna Therapeutics Inc.
13.7.1. Business Overview
13.7.2. Key Executives
13.7.3. Product & Services
13.8. Protalix Biotherapeutics Inc.
13.8.1. Business Overview
13.8.2. Key Executives
13.8.3. Product & Services
13.9. Sanofi S.A.
13.9.1. Business Overview
13.9.2. Key Executives
13.9.3. Product & Services
13.10. Shire Plc.
13.10.1. Business Overview
13.10.2. Key Executives
13.10.3. Product & Services
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing